Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors
about
Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental ReproducibilityInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewViral quasispecies evolutionA Novel I221L Substitution in Neuraminidase Confers High-Level Resistance to Oseltamivir in Influenza B VirusesNew small-molecule drug design strategies for fighting resistant influenza ABinding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometryI222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) virusesCoadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with OseltamivirSynergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumoniaUnique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Two years after pandemic influenza A/2009/H1N1: what have we learned?Drug resistance in influenza A virus: the epidemiology and management.The pharmacological management of severe influenza infection - 'existing and emerging therapies'.Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variantsMolecular epidemiology of influenza A virus infection in Cyprus in four consecutive seasons (2009 pandemic-2013).A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.Mass spectrometry-based comparative sequence analysis for the genetic monitoring of influenza A(H1N1)pdm09 virus.Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility.Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase.Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent childDetection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand.The global spread of drug-resistant influenza.Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virusPeramivir for the treatment of influenza.In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275YPresence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) virusesEarly activation of MAP kinases by influenza A virus X-31 in murine macrophage cell linesEpistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza virusesEvolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
P2860
Q24288661-1835886D-50C6-4BFF-91FA-63039C8AC644Q26860032-FD4CE4FF-A078-42EA-A799-95D1204E7307Q27013917-5FBE6C75-2ED9-4381-933A-82ECF1F92048Q27683640-EDA13F91-B4C8-4F48-97E2-A332A3DE1743Q28080554-04840BFA-8EBD-4720-BFAB-15CBCFC4C022Q28292279-A6AE3477-205A-4BB7-9E2E-83B628D837E4Q28533778-6C052565-FB6F-4AC8-B8A9-8DB611364817Q28548533-510CA520-9EB9-4A9A-A355-1157C2B217ADQ28732374-4FAA039A-76BB-4A74-9DAD-6DC11D405905Q30202859-3AB858C9-C08E-489F-9BBD-5987AC779A06Q30224656-1E23B2A7-EB74-402F-A9F1-98F1FBF5C2DDQ30234600-F603995A-2A5A-45D3-A796-EE0E1D6A22D5Q30243907-14723511-A1DA-4FB2-AA91-232ED6537E54Q30352666-4635AF55-A13F-4C75-8569-B7159ACA28D5Q30354880-9D3A1FC7-486E-4532-A2E8-9F51E7745BE9Q30357193-C9D401B4-EB3E-4469-9DE9-8163AF454EBFQ30361002-159CF41F-F179-48A9-A7D0-19B6FBF34705Q30367861-6D63A1D2-41A4-4022-A29E-DEE7BAEA36C0Q30378860-A8F3FA7F-C3A0-4F00-B5A2-89BB184FD002Q30392198-97969E5D-F3E7-4789-990F-0A77ADBAA363Q30405350-C64EC9CB-4491-4899-A1DD-51522932E7F2Q30405407-FEFD76DD-9957-4ADA-A6EE-DB225C6CF82BQ30405714-EEDEC942-5912-41AF-91E9-A77200B008B7Q30406360-C9613B59-6AE7-4CBD-BA7A-7F8FC69C4C74Q30411116-6A6BAD18-CB5D-4FEC-B31C-DF1C4AD723E4Q30413154-6EE169DD-AC7A-457E-B751-40D7D18B5E07Q30416440-C6533DE9-33D5-4417-8898-29EE224C1443Q30419391-356BE2F0-FB48-43DC-BEBD-95A97B33B343Q30419738-4F4C461A-A464-4C3E-B2FD-71E181F09A6DQ30420810-A0C73B4B-A747-42C3-A5EC-30220CB1F4D4Q30421139-06C87F06-128B-434C-A27C-85414EF15CAAQ30422779-96601721-5D19-4CD1-A194-34AA47E44392Q30424185-B5AD1786-9309-4EDB-BD71-D4BD24F14736Q30426441-E1B6D494-18C7-4B81-BA3A-FC4118A3DD0FQ30429450-AA205519-3C7E-4BC9-8152-FA269A9D68D8Q34057596-38D7E83F-EDE3-4259-89AD-7DAE297285F6Q34102756-E35EEF97-68BD-440A-8E80-AF1365251D69Q34104767-50C391E4-FD0A-4362-8468-1570564F0CAEQ34339407-C12FC6B5-EA8F-4646-B598-9D845DB0B4B7Q34597005-A368EEB0-B58F-43FB-AE24-B053D756932E
P2860
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Generation and characterizatio ...... nt to neuraminidase inhibitors
@ast
Generation and characterizatio ...... nt to neuraminidase inhibitors
@en
type
label
Generation and characterizatio ...... nt to neuraminidase inhibitors
@ast
Generation and characterizatio ...... nt to neuraminidase inhibitors
@en
prefLabel
Generation and characterizatio ...... nt to neuraminidase inhibitors
@ast
Generation and characterizatio ...... nt to neuraminidase inhibitors
@en
P2093
P2860
P356
P1476
Generation and characterizatio ...... nt to neuraminidase inhibitors
@en
P2093
Andrés Pizzorno
Guy Boivin
Xavier Bouhy
Yacine Abed
P2860
P356
10.1093/INFDIS/JIQ010
P407
P577
2011-01-01T00:00:00Z